- Home
- LANV vs AVIR Comparison
LANV vs AVIR Comparison
Compare LANV & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- AVIR
- Stock Information
- Founded
- LANV 2015
- AVIR 2012
- Country
- LANV China
- AVIR United States
- Employees
- LANV N/A
- AVIR N/A
- Industry
- LANV Blank Checks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LANV Finance
- AVIR Health Care
- Exchange
- LANV Nasdaq
- AVIR Nasdaq
- Market Cap
- LANV 258.1M
- AVIR 273.7M
- IPO Year
- LANV N/A
- AVIR 2020
- Fundamental
- Price
- LANV $2.40
- AVIR $2.74
- Analyst Decision
- LANV
- AVIR Hold
- Analyst Count
- LANV 0
- AVIR 1
- Target Price
- LANV N/A
- AVIR $6.00
- AVG Volume (30 Days)
- LANV 47.6K
- AVIR 460.5K
- Earning Date
- LANV 04-30-2025
- AVIR 05-12-2025
- Dividend Yield
- LANV N/A
- AVIR N/A
- EPS Growth
- LANV N/A
- AVIR N/A
- EPS
- LANV N/A
- AVIR N/A
- Revenue
- LANV $340,211,202.00
- AVIR N/A
- Revenue This Year
- LANV $11.74
- AVIR N/A
- Revenue Next Year
- LANV $11.11
- AVIR N/A
- P/E Ratio
- LANV N/A
- AVIR N/A
- Revenue Growth
- LANV N/A
- AVIR N/A
- 52 Week Low
- LANV $0.91
- AVIR $2.60
- 52 Week High
- LANV $2.69
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- LANV 59.64
- AVIR 46.47
- Support Level
- LANV $1.71
- AVIR $2.46
- Resistance Level
- LANV $2.58
- AVIR $3.01
- Average True Range (ATR)
- LANV 0.20
- AVIR 0.17
- MACD
- LANV 0.03
- AVIR -0.02
- Stochastic Oscillator
- LANV 70.56
- AVIR 45.60
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).